GLP1R and metabolic dysfunction-associated steatotic liver disease: Clarifying the relationship between plasma ceramides and NAFLD severity in patients with type 2 diabetes would add to our understanding of the interplay between ceramides and NAFLD in this population, especially in the era of antidiabetic drugs such as the GLP-1 receptor agonists that can influence plasma ceramide levels [8].